Prestige Biopharma IDC Files Patent for Next-Generation Antibody Delivery Platform ‘IDC224’

Prestige Biopharma IDC Files Patent for Next-Generation Antibody Delivery Platform ‘IDC224’

Prestige Biopharma IDC, the innovative drug discovery center of Prestige Biopharma, announced on the 21st that it has filed a patent for its next-generation subcutaneous (SC) platform, ‘IDC224,’ designed to improve both patient convenience and therapeutic efficacy of antibody treatments.

According to the company, most antibody therapeutics are currently administered via intravenous (IV) infusion, which typically takes over an hour and requires medical assistance. In contrast, subcutaneous (SC) injection can be administered in a much shorter time, significantly improving patient convenience. It is also considered a more suitable option for patients who require repeated dosing and may be at risk of vascular damage. As a result, the pharmaceutical and biotech industry is increasingly shifting from IV to SC administration.

However, due to the molecular characteristics of antibody drugs, it is technically challenging to deliver them stably at high concentrations, which has limited their transition to SC formulations. Prestige Biopharma IDC developed IDC224 to address these limitations.

The IDC224 platform is designed to be administered as a liquid injection, which then transforms into a gel form in the body in response to body temperature, allowing for sustained drug release. This enables prolonged therapeutic effects and reduced dosing frequency, while also ensuring uniform delivery of high-concentration antibodies to enhance delivery efficiency. In addition, the platform utilizes biodegradable materials, offering advantages in terms of safety.

A representative leading the development of the IDC224 patent stated, “This platform was developed with a focus on improving the administration method, drug delivery efficiency, and patient convenience of antibody therapeutics.” They added, “In preclinical studies, the application of this platform in gastric, ovarian, and breast cancer models demonstrated improved therapeutic efficacy compared to conventional methods.”

They further noted that this patent is a follow-up to an existing composition patent and is significant as a use invention that newly identifies the anticancer efficacy of the composition.

In particular, the technology has been designed to enable the subcutaneous (SC) formulation of Prestige Biopharma’s trastuzumab biosimilar, Tuznue®. The product is currently approved and marketed in Europe, and this development is expected to enhance product competitiveness and provide a differentiated administration option.

A company official from Prestige Biopharma IDC stated, “The IDC224 platform is designed to enhance the durability of antibody efficacy while also improving ease of administration. We plan to expand its application to various antibody therapeutics in the future.”

Meanwhile, the company also announced that it has completed the registration of a substance patent in Brazil for its pancreatic cancer antibody drug PBP1510, which is currently under global clinical development, further strengthening its pipeline portfolio.

Source: : newspim(https://www.newspim.com/news/view/20260421000641)